Translational CNS Summit
|Event Date/Time: Oct 22, 2013||End Date/Time: Oct 24, 2013|
Focusing on how the biggest pitfalls in your CNS drug development programme can be avoided; the Translational CNS Summit is your chance to analyse what’s gone wrong in the past? Why it continues? And how it can be fixed?
After the success of the Translational CNS Summit in Boston we wanted to replicate the passionate debates, the ideas sharing and the open and frank discussion in Europe
The Summit is about finding ways to tap into the huge commercial opportunity CNS diseases represent. Discovering the technologies and techniques that are proving beneficial to drug development and avoiding the approaches that have historically led to failure.
New strategies. The potential of imaging. The role of biomarkers. And the improvement of animal models are all up for debate.
- New strategies: Discover how the worlds biggest drug developers includingAbbVie, BMS and Eli Lilly are adapting their strategies to minimize clinical attrition in their CNS pipelines
- Imaging: Imaging techniques are aiding translation; learn from imaging experts at Amgen and UBC and discover how you can optimise these processes within your drug development
- Biomarkers: Increase your understanding of the role of biomarkers in CNS drug development. Learn how Lundbeck and Boehringer Ingelheim are ensuring their biomarkers for CNS diseases are as reliable as possible
- Animal Models: Explore improvements in animal modelling by hearing from disease model leaders from Janssen and Roche. Learn how we can increase their predictive validity of the models we use and compensate for their obvious limitations
The Summit will bring together CNS leaders from across Europe and the globe to discuss, deliberate and decide how to smooth the translation of CNS therapies into the market and how to start seeing a return on the historic investments made in the CNS field.
If you are passionate about securing the future of CNS drug development, if you have have ideas to share, opinions on what needs to change and an ability to make things happen you need to attend the Translational CNS Summit.
Who’s the meeting for?
This meeting is for anyone who wants to increase the translational potential of CNS therapies and meet the massive unmet medical need that CNS diseases represent. That means...
Large drug developers – Heads of CNS programmes and research scientists who will benefit from learning to apply new translational approaches in their drug development
Small and medium drug developers who are experiencing similar challenges as large pharma and are looking to find ways to overcome the challenges of CNS drug development
Providers of services or products specifically targeted at people working in the CNS space
People from research institutes who are working on refining translational approaches that will benefit CNS drug development.